1: Tan J, Zhong M, Hu Y, Pan G, Yao J, Tang Y, Duan H, Jiang Y, Shan W, Lin J, Liu Y, Huang J, Zheng H, Zhou Y, Fu G, Li Z, Xu B, Zha J. Ritanserin suppresses acute myeloid leukemia by inhibiting DGKα to downregulate phospholipase D and the Jak-Stat/MAPK pathway. Discov Oncol. 2023 Jul 1;14(1):118. doi: 10.1007/s12672-023-00737-9. PMID: 37392305; PMCID: PMC10314883.
2: Zhou D, Liu T, Rao X, Jie X, Chen Y, Wu Z, Deng H, Zhang D, Wang J, Wu G. Targeting diacylglycerol kinase α impairs lung tumorigenesis by inhibiting cyclin D3. Thorac Cancer. 2023 May;14(13):1179-1191. doi: 10.1111/1759-7714.14851. Epub 2023 Mar 25. PMID: 36965165; PMCID: PMC10151139.
3: Jiang SS, Gong MN, Rao W, Chai W, Chen WZ, Zhang X, Nie HB, Xu RS. 5-Hydroxytryptamine: a potential therapeutic target in amyotrophic lateral sclerosis. Neural Regen Res. 2023 Sep;18(9):2047-2055. doi: 10.4103/1673-5374.367929. PMID: 36926731; PMCID: PMC10233787.
4: Afolabi JM, Michael OS, Falayi OO, Kanthakumar P, Mankuzhy PD, Soni H, Adebiyi A. Activation of renal vascular smooth muscle TRPV4 channels by 5-hydroxytryptamine impairs kidney function in neonatal pigs. Microvasc Res. 2023 Jul;148:104516. doi: 10.1016/j.mvr.2023.104516. Epub 2023 Mar 6. Erratum in: Microvasc Res. 2024 Jul;154:104696. doi: 10.1016/j.mvr.2024.104696. PMID: 36889668; PMCID: PMC10258165.
5: La Marca JE, Ely RW, Diepstraten ST, Burke P, Kelly GL, Humbert PO, Richardson HE. A Drosophila chemical screen reveals synergistic effect of MEK and DGKα inhibition in Ras-driven cancer. Dis Model Mech. 2023 Mar 1;16(3):dmm049769. doi: 10.1242/dmm.049769. Epub 2023 Apr 3. PMID: 36861754; PMCID: PMC10110402.
6: Yamamoto R, Ito T, Furuyama T, Ono M, Kato N. 5-HT and α-m-5-HT attenuate excitatory synaptic transmissions onto the lateral amygdala principal neurons via presynaptic 5-HT1B receptors. Biochem Biophys Res Commun. 2022 Oct 8;624:28-34. doi: 10.1016/j.bbrc.2022.07.076. Epub 2022 Jul 31. PMID: 35932576.
7: Li YX, Li JH, Guo Y, Tao ZY, Qin SH, Traub RJ, An H, Cao DY. Oxytocin inhibits hindpaw hyperalgesia induced by orofacial inflammation combined with stress. Mol Pain. 2022 Jan-Dec;18:17448069221089591. doi: 10.1177/17448069221089591. PMID: 35266833; PMCID: PMC9047792.
8: Kusljic S, van den Buuse M, Gogos A. Reassessment of amphetamine- and phencyclidine-induced locomotor hyperactivity as a model of psychosis-like behavior in rats. J Integr Neurosci. 2022 Jan 28;21(1):17. doi: 10.31083/j.jin2101017. PMID: 35164453.
9: García-Pedraza JÁ, Fernández-González JF, López C, Martín ML, Alarcón- Torrecillas C, Rodríguez-Barbero A, Morán A, García-Domingo M. Oral fluoxetine treatment changes serotonergic sympatho-regulation in experimental type 1 diabetes. Life Sci. 2022 Mar 15;293:120335. doi: 10.1016/j.lfs.2022.120335. Epub 2022 Jan 18. PMID: 35051421.
10: Granade ME, Manigat LC, Lemke MC, Purow BW, Harris TE. Identification of ritanserin analogs that display DGK isoform specificity. Biochem Pharmacol. 2022 Mar;197:114908. doi: 10.1016/j.bcp.2022.114908. Epub 2022 Jan 6. PMID: 34999054; PMCID: PMC8858877.
11: Oved K, Zennaro L, Dorot O, Zerbib J, Frank E, Roux LN, Bremond-Gignac D, Pichinuk E, Aberdam D. Ritanserin, a potent serotonin 2A receptor antagonist, represses MEK/ERK signalling pathway to restore PAX6 production and function in aniridia-like cellular model. Biochem Biophys Res Commun. 2021 Dec 10;582:100-104. doi: 10.1016/j.bbrc.2021.10.036. Epub 2021 Oct 16. PMID: 34700241.
12: García-Pedraza JÁ, López C, Fernández-González JF, Martín ML, Morán A, García-Domingo M. Vascular sympathetic neurotransmission and its serotonergic regulation are modified by chronic fluoxetine treatment. J Pharmacol Sci. 2021 Sep;147(1):48-57. doi: 10.1016/j.jphs.2021.05.008. Epub 2021 May 23. PMID: 34294372.
13: Kovalenko A, Sanin A, Kosmas K, Zhang L, Wang J, Akl EW, Giannikou K, Probst CK, Hougard TR, Rue RW, Krymskaya VP, Asara JM, Lam HC, Kwiatkowski DJ, Henske EP, Filippakis H. Therapeutic Targeting of DGKA-Mediated Macropinocytosis Leads to Phospholipid Reprogramming in Tuberous Sclerosis Complex. Cancer Res. 2021 Apr 15;81(8):2086-2100. doi: 10.1158/0008-5472.CAN-20-2218. Epub 2021 Feb 16. PMID: 33593821; PMCID: PMC8137542.
14: Okada T, Shioda K, Makiguchi A, Suda S. Risperidone and 5-HT2A Receptor Antagonists Attenuate and Reverse Cocaine-Induced Hyperthermia in Rats. Int J Neuropsychopharmacol. 2020 Dec 29;23(12):811-820. doi: 10.1093/ijnp/pyaa065. PMID: 32821948; PMCID: PMC7770520.
15: Jones MT, Strassnig MT, Harvey PD. Emerging 5-HT receptor antagonists for the treatment of Schizophrenia. Expert Opin Emerg Drugs. 2020 Jun;25(2):189-200. doi: 10.1080/14728214.2020.1773792. Epub 2020 Jun 8. PMID: 32449404.
16: Poyurovsky M, Weizman A. Treatment of Antipsychotic-Induced Akathisia: Role of Serotonin 5-HT2a Receptor Antagonists. Drugs. 2020 Jun;80(9):871-882. doi: 10.1007/s40265-020-01312-0. PMID: 32385739.
17: Liu L, Yudin Y, Rohacs T. Diacylglycerol kinases regulate TRPV1 channel activity. J Biol Chem. 2020 Jun 12;295(24):8174-8185. doi: 10.1074/jbc.RA119.012505. Epub 2020 Apr 28. PMID: 32345612; PMCID: PMC7294095.
18: Fusi F, Trezza A, Sgaragli G, Spiga O, Saponara S, Bova S. Ritanserin blocks CaV1.2 channels in rat artery smooth muscles: electrophysiological, functional, and computational studies. Acta Pharmacol Sin. 2020 Sep;41(9):1158-1166. doi: 10.1038/s41401-020-0370-1. Epub 2020 Mar 4. PMID: 32132658; PMCID: PMC7608335.
19: Cervantes-Ramírez V, Canto-Bustos M, Aguilar-Magaña D, Pérez-Padilla EA, Góngora-Alfaro JL, Pineda JC, Atzori M, Salgado H. Citalopram reduces glutamatergic synaptic transmission in the auditory cortex via activation of 5-HT1A receptors. Neuroreport. 2019 Dec 18;30(18):1316-1322. doi: 10.1097/WNR.0000000000001366. PMID: 31714483.
20: Velnati S, Ruffo E, Massarotti A, Talmon M, Varma KSS, Gesu A, Fresu LG, Snow AL, Bertoni A, Capello D, Tron GC, Graziani A, Baldanzi G. Identification of a novel DGKα inhibitor for XLP-1 therapy by virtual screening. Eur J Med Chem. 2019 Feb 15;164:378-390. doi: 10.1016/j.ejmech.2018.12.061. Epub 2018 Dec 26. PMID: 30611057; PMCID: PMC6599760.